Last $38.04 USD
Change Today +0.33 / 0.88%
Volume 398.6K
As of 8:10 PM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

cardiovascular systems inc (CSII) Snapshot

Open
$38.78
Previous Close
$37.71
Day High
$39.11
Day Low
$37.63
52 Week High
03/2/15 - $39.11
52 Week Low
10/1/14 - $23.15
Market Cap
1.2B
Average Volume 10 Days
211.7K
EPS TTM
$-1.06
Shares Outstanding
31.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CARDIOVASCULAR SYSTEMS INC (CSII)

cardiovascular systems inc (CSII) Related Bloomberg News

View More Bloomberg News

cardiovascular systems inc (CSII) Related Businessweek News

No Related Businessweek News Found

cardiovascular systems inc (CSII) Details

Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and markets devices for the treatment of vascular diseases. Its products include catheter-based platforms, such as the Stealth 360° Peripheral Orbital Atherectomy System (OAS), Diamondback 360 Peripheral OAS, Stealth 360° peripheral artery disease (PAD) System, Diamondback 360° PAD System, and Diamondback Predator 360° PAD System that are used for the treatment of a range of plaque types in leg arteries above and below the knee. The company markets its products through direct sales force to hospitals and office-based labs. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.

479 Employees
Last Reported Date: 08/28/14
Founded in 1989

cardiovascular systems inc (CSII) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer
Total Annual Compensation: $330.7K
Chief Healthcare Policy Officer
Total Annual Compensation: $318.7K
Chief Administrative Officer, Compliance Offi...
Total Annual Compensation: $296.4K
Executive Vice President of Sales & Marketing
Total Annual Compensation: $305.4K
Compensation as of Fiscal Year 2014.

cardiovascular systems inc (CSII) Key Developments

Cardiovascular Systems Inc. to Present Orbit II Two-Year Coronary Data at 2015 Cardiovascular Research Technologies Conference

Cardiovascular Systems Inc. will release two-year data from its ORBIT II study of the company’s Diamondback 360® Coronary Orbital Atherectomy System (OAS) in treating severely calcified lesions at the 2015 Cardiovascular Research Technologies (CRT) conference in Washington, D.C., Feb. 21-24, 2015. The pivotal ORBIT II study evaluated the safety and effectiveness of the company’s orbital atherectomy technology, and CSI completed ORBIT II enrollment of 443 patients at 49 U.S. medical centers in November 2012. In October 2013, the company received PMA approval from the U.S. Food and Drug Administration to market its Diamondback 360 Coronary Orbital Atherectomy System as a treatment for severely calcified coronary arteries. It is estimated that significant arterial calcium is present in nearly 40% of patients treated with interventional therapies. Calcium can cause complications, including difficult stent deployment, dissections and, when stents are under expanded, it can result in the need for a coronary bypass. Since receiving approval, CSI has continued the controlled commercial launch of its Diamondback Coronary Orbital Atherectomy System (OAS) in the United States and more than 4,000 patients have been treated using CSI’s unique technology.

Cardiovascular Systems Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 08:25 AM

Cardiovascular Systems Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 08:25 AM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: David L. Martin, Chief Executive Officer, President and Director.

Cardiovascular Systems, Inc. Reports Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended December 31, 2014; Provides Earnings Guidance for the Third Quarter Ending March 31, 2015

Cardiovascular Systems Inc. reported unaudited consolidated financial results for the second quarter and six months ended December 31, 2014. For the second-quarter, the company’s revenues increased 38% to $44.7 million, from $32.3 million in the second quarter of fiscal 2014. Loss from operations was $5,252,000 compared to $7,495,000 last year. Net loss and comprehensive loss was $5,273,000 or $0.17 per basic and diluted share compared to $8,658,000 or $0.32 per basic and diluted share last year. Adjusted LBITDA was $1,316,000 compared to $4,627,000 last year. Excluding net coronary investments, adjusted EBITDA was positive for the quarter. For the first six months, the company reported revenues of $86,086,000 compared to revenues of $62,103,000 for the same period a year ago. Loss from operations was $13,442,000 compared to $14,342,000 last year. Net loss and comprehensive loss was $13,497,000 or $0.43 per basic and diluted share compared to $15,950,000 or $0.61 per basic and diluted share last year. Adjusted LBITDA was $5,526,000 compared to $8,858,000 last year. Excluding net coronary investments, adjusted EBITDA was positive year to date. For the third quarter ending March 31, 2015, the company anticipates revenue growth of 32% to 36% over the third quarter of fiscal 2014, to a range of $46.0 million to $47.7 million. Gross profit as a percentage of revenues similar to the second quarter of fiscal 2015. Net loss in the range of $10.0 million to $11.0 million, or loss per common share ranging from $0.32 to $0.35, assuming 31.6 million average shares outstanding.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CSII:US $38.04 USD +0.33

CSII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $17.76 USD +0.08
CryoLife Inc $10.51 USD +0.03
Endologix Inc $16.00 USD +0.23
Spectranetics Corp/The $34.53 USD +0.72
Vascular Solutions Inc $29.50 USD +0.32
View Industry Companies
 

Industry Analysis

CSII

Industry Average

Valuation CSII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.4x
Price/Book 8.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDIOVASCULAR SYSTEMS INC, please visit www.csi360.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.